Core Viewpoint - Tiger Medical (300347.SZ) reported a revenue of 6.833 billion yuan for the year 2025, reflecting a year-on-year growth of 3.48% [1] - The net profit attributable to shareholders reached 888 million yuan, showing a significant year-on-year increase of 119.15% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 355 million yuan, which represents a year-on-year decrease of 58.47% [1] - The basic earnings per share (EPS) stood at 1.04 yuan, and the company proposed a cash dividend of 1.26 yuan per 10 shares (tax included) to all shareholders [1] Financial Performance - Revenue for 2025: 6.833 billion yuan, up 3.48% year-on-year [1] - Net profit attributable to shareholders: 888 million yuan, up 119.15% year-on-year [1] - Net profit after deducting non-recurring items: 355 million yuan, down 58.47% year-on-year [1] - Basic EPS: 1.04 yuan [1] Dividend Proposal - Proposed cash dividend: 1.26 yuan per 10 shares (tax included) [1]

Core Viewpoint - Shanghai Pharmaceuticals (02607.HK) reported a revenue of 283.58 billion RMB for the fiscal year 2025, reflecting a year-on-year growth of 3.03% [1] Revenue Breakdown - The pharmaceutical manufacturing segment generated sales of 24.52 billion RMB, an increase of 3.33% year-on-year [1] - The pharmaceutical distribution segment achieved sales of 259.06 billion RMB, growing by 3.00% year-on-year [1] Profit Analysis - The net profit attributable to shareholders reached 5.73 billion RMB, marking a significant increase of 25.74% year-on-year, primarily due to a one-time special gain from the change in accounting treatment of Hutchison Whampoa from an equity method to a subsidiary [1] - After excluding one-time special gains and losses, the net profit attributable to shareholders was 4.72 billion RMB, which represents a decline of 5.56% year-on-year [1] Segment Contribution - The industrial segment contributed a profit of 2.04 billion RMB [1] - The commercial segment contributed a profit of 3.46 billion RMB [1] - Profits from major associated enterprises amounted to 325 million RMB [1]

Core Viewpoint - Shanghai Pharmaceuticals (02607.HK) reported a revenue of 283.58 billion RMB for the fiscal year 2025, reflecting a year-on-year growth of 3.03% [1] Revenue Breakdown - The pharmaceutical manufacturing segment generated sales of 24.52 billion RMB, an increase of 3.33% year-on-year [1] - The pharmaceutical distribution segment achieved sales of 259.06 billion RMB, growing by 3.00% year-on-year [1] Profit Analysis - The net profit attributable to shareholders reached 5.73 billion RMB, marking a significant increase of 25.74% year-on-year, primarily due to a one-time special gain from the change in accounting treatment of Hutchison Whampoa from equity method to subsidiary accounting [1] - After excluding one-time special gains and losses, the net profit attributable to shareholders was 4.72 billion RMB, which represents a decline of 5.56% year-on-year [1] Segment Contribution - The industrial segment contributed a profit of 2.04 billion RMB [1] - The commercial segment contributed a profit of 3.46 billion RMB [1] - Profits from major associated enterprises amounted to 325 million RMB [1]

Market Overview - The A-share market showed signs of recovery in early trading, with the Shanghai Composite Index rebounding after a drop of over 1%, while the ChiNext and Shenzhen Composite Indexes narrowed their declines [1] - The total trading volume in the Shanghai and Shenzhen markets reached 1.32 trillion yuan, an increase of 180.3 billion yuan compared to the previous trading day [1] Sector Performance - The pharmaceutical sector was notably active, with Meinuo Pharma achieving six consecutive trading limits, and both Tianyao Pharmaceutical and Lianhuan Pharmaceutical securing two consecutive limits [3] - The commercial aerospace concept also saw a rebound, with Shenjian Co. achieving three consecutive limits, and Zengsheng Technology hitting three limits in four days, while Aerospace Power and Zhongheng Design reached their daily limits [3] - Agricultural stocks experienced a rapid rise, with Jinjian Rice Industry, Beidahuang, and New Agricultural Development all hitting their daily limits [3] - The non-ferrous metals and aluminum sector strengthened collectively, with Minfa Aluminum, Chang Aluminum, and Tianshan Aluminum all reaching their daily limits [3] Declining Stocks - The power sector faced significant declines, with Huadian Energy and Jinkong Power hitting their daily limits down, and several other stocks like Yinxing Energy and Ningbo Energy also reaching their daily limits [3] - At market close, the Shanghai Composite Index rose by 0.23%, while the Shenzhen Composite Index fell by 0.12%, and the ChiNext Index decreased by 0.5% [3]

Group 1 - The report highlights that the North Exchange has entered a relatively low valuation phase, presenting a window for investment in hard technology and newly listed stocks [2][12][18] - The North Exchange's valuation has become more attractive, with the North 50 and North Specialized New indices showing a decline in performance, indicating a potential recovery opportunity [3][14][39] - The report suggests focusing on companies with low valuations in high-tech sectors, particularly those benefiting from the ongoing geopolitical tensions, such as the US-Iran conflict [3][40] Group 2 - The North Exchange's market performance shows that the North 50 index has decreased, with a current P/E ratio of 41.98X, indicating a significant valuation gap compared to other indices [3][11][18] - The report identifies specific sectors such as high-end equipment, information technology, and chemical new materials as having favorable P/E ratios, with the highest being 85.53X in information technology [3][18][41] - The report recommends a stock pool that includes companies like Wanyuantong and Beitery, which are positioned well within their respective industries and have shown strong growth potential [3][41][44] Group 3 - The North Exchange has seen a significant drop in daily trading volume, with an average of 135.53 billion yuan, down 14.80% from the previous week, indicating a decline in liquidity [27][30][32] - The report notes that the average daily turnover rate for the North 50 and North Specialized New indices has also decreased, reflecting a broader trend of reduced trading activity [30][32] - The report emphasizes the importance of monitoring liquidity trends as they can impact investment strategies and market sentiment [27][30][32] Group 4 - The report outlines the current IPO status, with three companies having passed the review and three awaiting approval, indicating ongoing activity in the North Exchange's listing process [4][8] - The report provides insights into the performance of newly listed companies, highlighting significant first-day gains, such as a 136.56% increase for Puang Medical [4][11][41] - The North Exchange continues to cultivate companies that may transition to larger exchanges, showcasing its role as a breeding ground for future market leaders [4][11][41]

Market Overview - The A-share market opened lower but closed higher, with the Shenzhen Component Index rising over 1% [1] - The total trading volume in the Shanghai and Shenzhen markets was 1.85 trillion, a decrease of 903 billion compared to the previous trading day [1][5] - More than 4,300 stocks in the market experienced gains, indicating a broad-based rally [1] Sector Performance - The lithium battery industry chain saw significant gains, with multiple stocks hitting the daily limit, including Rongjie Co., Ltd. with four consecutive limit-ups and Shida Shenghua with two consecutive limit-ups [1] - The pharmaceutical sector also performed well, with Keta Bio hitting the daily limit and several other stocks showing strong upward momentum [1] - The chemical sector was active, with stocks like Suli Co., Ltd. and Luban Chemical hitting the daily limit [1] Declines - In contrast, several stocks in the green energy sector experienced declines, with Liaoning Energy hitting the limit down and other companies like Jieneng Wind Power and Hunan Development also facing significant drops [2] Closing Statistics - At the close, the Shanghai Composite Index rose by 0.63%, the Shenzhen Component Index increased by 1.13%, and the ChiNext Index gained 0.71% [3][4]

Market Overview - The A-share market opened lower but rebounded, with all three major indices turning positive. The half-day trading volume in the Shanghai and Shenzhen markets was 1.14 trillion, a decrease of 84.3 billion compared to the previous trading day [1]. Stock Performance - Over 3,700 stocks in the market rose, indicating a broad-based rally [2]. Sector Highlights - The lithium mining sector saw significant gains, with Rongjie Co. achieving a four-day consecutive rise, while Jiangte Electric, Jinyuan Co., and Shengxin Lithium Energy hit the daily limit [3]. - The pharmaceutical sector also performed strongly, with Keta Bio reaching the daily limit, Meinuohua achieving five gains in six days, and Wanbangde recording three gains in four days. Lianhuan Pharmaceutical and Shuanglu Pharmaceutical also hit the daily limit [3]. - The chemical sector was active, with Sully Co., Lubai Chemical, and Jinzheng all reaching the daily limit [3]. Declines - In contrast, several stocks in the green energy sector experienced declines, with Liaoning Energy hitting the daily limit down, and both Jieneng Wind Power and Haili Wind Power seeing significant drops [4]. Closing Summary - By the end of the trading session, the Shanghai Composite Index rose by 0.26%, the Shenzhen Component Index increased by 0.93%, and the ChiNext Index was up by 0.83% [5].

Market Overview - On March 26, the Hang Seng Index fell by 479 points (1.9%) to close at 24,856, dropping below the 25,000 mark[1] - The Hang Seng Tech Index decreased by 161 points (3.2%) to close at 4,761[1] - Total market turnover shrank to HKD 261.7 billion from HKD 350.9 billion the previous day[1] Geopolitical Impact - Iran rejected the U.S. ceasefire proposal, leading to increased market volatility and rising oil prices[1] - U.S. stock markets also showed weakness, with the Dow Jones down 469 points (1.0%) to 45,960, and the Nasdaq down 521 points (2.3%) to 21,408[2] Automotive Sector - In the first two months of the year, China's automobile exports reached 1.55 million units, a year-on-year increase of 61%[3] - Exports of new energy vehicles (NEVs) totaled 670,000 units, up 88% year-on-year[3] - In February alone, NEV exports surged by 120% year-on-year, reaching 320,000 units[4] Industry Performance - The automotive sector experienced a significant pullback, with most stocks declining, except for a few like SOTY and Leap Motor, which rose by 1.3%-1.4%[4] - The renewable energy sector saw a general decline, with stocks like Xinyi Solar and LONGi Green Energy dropping by 3.4%-4.1%[4] - Pharmaceutical stocks also fell, with CSPC Pharmaceutical reporting a 10.4% decline in revenue to HKD 26.01 billion for 2025[4]

Market Overview - The Asia-Pacific stock markets experienced a collective adjustment, with A-shares falling over 1% and the Shanghai Composite Index closing at 3889.08 points, down 1.09% [1][2] - The Hong Kong stock market also saw significant declines, with the Hang Seng Index dropping 1.89% to 24856.43 points and the Hang Seng Tech Index falling 3.28% [2][3] - The Nikkei 225 Index in Japan decreased by 0.27%, while the South Korean Composite Index fell by 3.22% [3][4] Oil Prices - International oil prices rose again, with ICE Brent crude reaching over $100 per barrel, currently reported at $99.66 per barrel, and WTI crude above $90 per barrel [5][6] - The increase in oil prices is attributed to geopolitical tensions, particularly the recent drone attack on a Turkish oil tanker in the Black Sea, which has raised concerns about supply disruptions [6] Pharmaceutical Sector - The raw material pharmaceutical stocks saw a strong rally, with companies like Meinuohua and Sitai Li hitting the daily limit, and Hongyuan Pharmaceutical rising approximately 8% [8] - The price increase in chemical products, driven by rising oil prices and higher energy costs, is expected to lead to a price hike in raw pharmaceutical materials, benefiting the sector [11] Lithium Battery Sector - The lithium battery concept stocks showed active trading, with Haike Xinyuan rising over 16% and Zhongrui Co. increasing by over 10% [13][14] - Zimbabwe's extended ban on lithium exports is expected to impact global supply, as the country is a significant source of lithium for China, potentially leading to price increases in lithium products [15] Company Specifics - Huadian Liaoning Energy's stock experienced a significant rise, achieving a 9-day consecutive limit up, but closed with a 6.47% increase amid concerns about stock price volatility [17][19] - The company has confirmed that its production and operational activities remain normal, with no significant changes in market conditions or internal operations [19]

Core Viewpoint - The news highlights the strategic initiatives of Bohai Bank to enhance its financial services in support of the real economy and cross-border trade, aligning with national policies and economic growth targets. Group 1: Economic Growth and Financial Strategy - The government work report emphasizes the need to focus on the real economy and develop new productive forces, with a target economic growth rate of 4.5% to 5% for the year [1] - Bohai Bank aims to innovate financial products and services to support foreign trade and investment, transitioning from a passive to an active role in financial service delivery [1] Group 2: Cross-Border Trade Initiatives - Bohai Bank has launched the Free Trade Accounting Unit (FTU) model, which enhances its financial service capabilities and aligns with the requirements for free trade financial infrastructure [2] - The FTU model aims to improve centralized management and risk control in cross-border trade, facilitating the "going out" and "bringing in" of enterprises [2] Group 3: Financial Product Optimization - The bank has optimized its "Cross-Border Free Trade Pass" product system to integrate with FT account functions, covering various financial scenarios [3] - Bohai Bank has become the first legal entity bank in Tianjin to directly access the national CIPS infrastructure, enhancing its cross-border payment capabilities [3] Group 4: Support for Advanced Manufacturing - Bohai Bank is actively supporting the transformation of the advanced manufacturing sector, particularly through a strategic partnership with XPeng Motors to create a supply chain financial service platform [4] - The bank's collaboration with XPeng Motors leverages its experience with major automotive companies to provide tailored financial solutions [5] Group 5: Financial Performance and Future Goals - By the end of 2025, Bohai Bank's supply chain finance has supported 28 leading automotive enterprises with a total credit support nearing 40 billion yuan, and an annual financing scale of approximately 330 billion yuan, reflecting a year-on-year growth of over 27% [5] - The bank aims to enhance its operational management and focus on key industries such as artificial intelligence and new energy, while building a "financial + scenario" ecosystem to support the real economy [6]